{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:30:00Z","timestamp":1781659800195,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T00:00:00Z","timestamp":1621036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T00:00:00Z","timestamp":1621036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70-3157"],"award-info":[{"award-number":["70-3157"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00432-021-03623-5","type":"journal-article","created":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T05:02:45Z","timestamp":1621054965000},"page":"441-447","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic relevance of Ki67 expression in primary male breast cancer: determination of cut-off points by different evaluation methods and statistical examinations"],"prefix":"10.1007","volume":"148","author":[{"given":"Melanie","family":"Erices-Leclercq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Lubig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"F\u00f6rster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"F\u00f6rster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5763-9276","authenticated-orcid":false,"given":"Christian","family":"Rudlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,15]]},"reference":[{"key":"3623_CR1","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10549-016-3817-9","volume":"157","author":"S Bustreo","year":"2016","unstructured":"Bustreo S et al (2016) Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. Breast Cancer Res Treat 157:363\u2013371. https:\/\/doi.org\/10.1007\/s10549-016-3817-9","journal-title":"Breast Cancer Res Treat"},{"key":"3623_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdx651","volume":"29","author":"F Cardoso","year":"2018","unstructured":"Cardoso F et al (2018) Characterization of male breast cancer: results of the EORTC 10085\/TBCRC\/BIG\/NABCG International Male Breast Cancer Program. Ann Oncol 29:405\u2013417. https:\/\/doi.org\/10.1093\/annonc\/mdx651","journal-title":"Ann Oncol"},{"key":"3623_CR3","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/jnci\/djp082","volume":"101","author":"MC Cheang","year":"2009","unstructured":"Cheang MC et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736\u2013750. https:\/\/doi.org\/10.1093\/jnci\/djp082","journal-title":"J Natl Cancer Inst"},{"key":"3623_CR4","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","volume":"26","author":"AS Coates","year":"2015","unstructured":"Coates AS et al (2015) Tailoring therapies\u2013improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26:1533\u20131546. https:\/\/doi.org\/10.1093\/annonc\/mdv221","journal-title":"Ann Oncol"},{"key":"3623_CR5","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1093\/annonc\/mdt350","volume":"24","author":"C Denkert","year":"2013","unstructured":"Denkert C et al (2013) Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol 24:2786\u20132793. https:\/\/doi.org\/10.1093\/annonc\/mdt350","journal-title":"Ann Oncol"},{"key":"3623_CR6","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/jnci\/djr393","volume":"103","author":"M Dowsett","year":"2011","unstructured":"Dowsett M et al (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103:1656\u20131664. https:\/\/doi.org\/10.1093\/jnci\/djr393","journal-title":"J Natl Cancer Inst"},{"key":"3623_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/cncr.20312","volume":"101","author":"SH Giordano","year":"2004","unstructured":"Giordano SH et al (2004) Breast carcinoma in men: a population-based study. Cancer 101:51\u201357. https:\/\/doi.org\/10.1002\/cncr.20312","journal-title":"Cancer"},{"key":"3623_CR8","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206\u20132223. https:\/\/doi.org\/10.1093\/annonc\/mdt303","journal-title":"Ann Oncol"},{"key":"3623_CR9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03120","author":"MJ Hassett","year":"2020","unstructured":"Hassett MJ et al (2020) Management of male breast cancer: ASCO Guideline. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.19.03120","journal-title":"J Clin Oncol"},{"key":"3623_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/his.14091","author":"P Hoon Tan","year":"2020","unstructured":"Hoon Tan P et al (2020) The 2019 WHO classification of tumours of the breast. Histopathology. https:\/\/doi.org\/10.1111\/his.14091","journal-title":"Histopathology"},{"key":"3623_CR11","unstructured":"International Ki-67 in Breast Cancer Working G (2021) International Ki-67 in Breast Cancer Working Group. https:\/\/www.ki67inbreastcancerwg.org\/. Accessed 21 Mar 2021"},{"key":"3623_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-020-01066-3","author":"AMB Jylling","year":"2020","unstructured":"Jylling AMB, Jensen V, Lelkaitis G, Christiansen P, Nielsen SS, Lautrup MD (2020) Male breast cancer: clinicopathological characterization of a National Danish cohort 1980\u20132009. Breast Cancer. https:\/\/doi.org\/10.1007\/s12282-020-01066-3","journal-title":"Breast Cancer"},{"key":"3623_CR13","unstructured":"Krebsregisterdaten Zf (2020) Datenabfrage (2020). https:\/\/www.krebsdaten.de\/Krebs\/SiteGlobals\/Forms\/Datenbankabfrage\/datenbankabfrage_stufe2_form.html. Accessed 17 January 2020"},{"key":"3623_CR14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10555-018-9761-x","volume":"37","author":"RA Leon-Ferre","year":"2018","unstructured":"Leon-Ferre RA et al (2018) A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer Metastasis Rev 37:599\u2013614. https:\/\/doi.org\/10.1007\/s10555-018-9761-x","journal-title":"Cancer Metastasis Rev"},{"key":"3623_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/his.13880","volume":"75","author":"SCY Leung","year":"2019","unstructured":"Leung SCY et al (2019) Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. Histopathology 75:225\u2013235. https:\/\/doi.org\/10.1111\/his.13880","journal-title":"Histopathology"},{"key":"3623_CR16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.critrevonc.2017.03.013","volume":"113","author":"A Losurdo","year":"2017","unstructured":"Losurdo A et al (2017) Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: a review of the literature. Crit Rev Oncol Hematol 113:283\u2013291. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.03.013","journal-title":"Crit Rev Oncol Hematol"},{"key":"3623_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.breast.2020.03.005","volume":"51","author":"AF Maranta","year":"2020","unstructured":"Maranta AF, Broder S, Fritzsche C, Knauer M, Thurlimann B, Jochum W, Ruhstaller T (2020) Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution\u2019s Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer. Breast 51:120\u2013126. https:\/\/doi.org\/10.1016\/j.breast.2020.03.005","journal-title":"Breast"},{"key":"3623_CR18","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1634\/theoncologist.2014-0243","volume":"20","author":"G Masci","year":"2015","unstructured":"Masci G et al (2015) Clinicopathological and immunohistochemical characteristics in male breast cancer: a retrospective case series. Oncologist 20:586\u2013592. https:\/\/doi.org\/10.1634\/theoncologist.2014-0243","journal-title":"Oncologist"},{"key":"3623_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa201","author":"TO Nielsen","year":"2020","unstructured":"Nielsen TO et al (2020) Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djaa201","journal-title":"J Natl Cancer Inst"},{"key":"3623_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3109\/0284186X.2012.711952","volume":"52","author":"C Nilsson","year":"2013","unstructured":"Nilsson C et al (2013) Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact. Acta Oncol 52:102\u2013109. https:\/\/doi.org\/10.3109\/0284186X.2012.711952","journal-title":"Acta Oncol"},{"key":"3623_CR21","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659\u20131672. https:\/\/doi.org\/10.1056\/NEJMoa052306","journal-title":"N Engl J Med"},{"key":"3623_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/bcr2607","volume":"12","author":"EA Rakha","year":"2010","unstructured":"Rakha EA et al (2010) Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 12:207. https:\/\/doi.org\/10.1186\/bcr2607","journal-title":"Breast Cancer Res"},{"key":"3623_CR23","first-page":"138","volume":"8","author":"W Remmele","year":"1987","unstructured":"Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138\u2013140","journal-title":"Pathologe"},{"key":"3623_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1023\/B:BREA.0000019953.92921.7e","volume":"84","author":"C Rudlowski","year":"2004","unstructured":"Rudlowski C et al (2004) Her-2\/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat 84:215\u2013223. https:\/\/doi.org\/10.1023\/B:BREA.0000019953.92921.7e","journal-title":"Breast Cancer Res Treat"},{"key":"3623_CR25","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1002\/ijc.21646","volume":"118","author":"C Rudlowski","year":"2006","unstructured":"Rudlowski C et al (2006) Comparative genomic hybridization analysis on male breast cancer. Int J Cancer 118:2455\u20132460. https:\/\/doi.org\/10.1002\/ijc.21646","journal-title":"Int J Cancer"},{"key":"3623_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7\u201330. https:\/\/doi.org\/10.3322\/caac.21590","journal-title":"CA Cancer J Clin"},{"key":"3623_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ejca.2017.01.034","volume":"82","author":"MA Vermeulen","year":"2017","unstructured":"Vermeulen MA et al (2017) Pathological characterisation of male breast cancer: results of the EORTC 10085\/TBCRC\/BIG\/NABCG International Male Breast Cancer Program. Eur J Cancer 82:219\u2013227. https:\/\/doi.org\/10.1016\/j.ejca.2017.01.034","journal-title":"Eur J Cancer"},{"key":"3623_CR28","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1158\/1078-0432.CCR-12-3628","volume":"19","author":"G von Minckwitz","year":"2013","unstructured":"von Minckwitz G et al (2013) Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin Cancer Res 19:4521\u20134531. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3628","journal-title":"Clin Cancer Res"},{"key":"3623_CR29","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08473-y","author":"AD Williams","year":"2020","unstructured":"Williams AD, McGreevy CM, Tchou JC, De La Cruz LM (2020) Utility of oncotype DX in male breast cancer patients and impact on chemotherapy administration: a comparative study with female patients. Ann Surg Oncol. https:\/\/doi.org\/10.1245\/s10434-020-08473-y","journal-title":"Ann Surg Oncol"},{"key":"3623_CR30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00066-011-0032-9","volume":"188","author":"C Wittekind","year":"2012","unstructured":"Wittekind C (2012) Lymph nodes, tumour deposits, and TNM: are we getting better? 7th edition of UICC 2010 TNM classification of malignant tumors. Strahlenther Onkol 188:191\u2013192. https:\/\/doi.org\/10.1007\/s00066-011-0032-9","journal-title":"Strahlenther Onkol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03623-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03623-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03623-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T19:03:17Z","timestamp":1643482997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03623-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,15]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["3623"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03623-5","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,15]]},"assertion":[{"value":"24 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) our work. They have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The patient data, histopathological findings as well as treatment reports and follow-up data were collected with the approval of the appropriate institutional review boards from the hospital archives. The study was approved by the institutional local ethics committee. Data were blinded for statistical evaluations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}